ABBV ABBV アッヴィ

 ABBVのチャート


 ABBVの企業情報

symbol ABBV
会社名 AbbVie Inc (ABBV アッヴィ)
分野(sector)   
産業(industry)   
業種 医薬品   医療関連(Health Care)
概要 事業概要 アッヴィ(AbbVie Inc.)は研究型バイオ医薬品会社である。同社は各種医薬品の発見・開発・製造・販売に従事する。同社の製品はリウマチ学、胃腸病学と皮膚科学等の慢性自己免疫疾患、血液癌を含む腫瘍学、C型肝炎ウイルス(HCV)とヒト免疫不全ウイルス(HIV)を含むウイルス学、パーキンソン病と多発性硬化症等の神経学的障害、甲状腺疾患と嚢胞性線維症関連合併症を含む代謝性疾患、並びに他の健康状態の治療のために使用される。同社はHUMIRA(アダリムマブ)、腫瘍学製品、ウイルス学、追加のウイルス学製品、代謝またはホルモン製品、内分泌学製品、並びにDuopaおよびDuodopa(カルビドパおよびレボドパ)、麻酔薬およびZINBRYTA(ダクリズマブ)を含む他の製品を提供する。  アッヴィは米国の研究開発型バイオ医薬品企業。主にC型肝炎、神経学、免疫学、腫瘍学、慢性腎疾患および女性の疾患などの分野における医薬品の開発に取り組む。アボット・ラボラトリ―ズの研究開発医薬品部門の分離独立に伴い2013年度に設立。主力製品はリウマチ性関節炎や乾癬治療薬「ヒュミラ」など。本社はイリノイ州ノ―ス・シカゴ。  
本社所在地 847 932-7900
代表者氏名 Richard A. Gonzalez
代表者役職名 Chairman of the Board Chief Executive Officer
電話番号 +1 847-932-7900
設立年月日 41000
市場名 NYSE(ニューヨーク証券取引所)
ipoyear
従業員数 30000人
url www.abbvie.com
nasdaq_url
adr_tso
EBITDA EBITDA(百万ドル) 9148.00000
終値(lastsale)
時価総額(marketcap)
時価総額 時価総額(百万ドル) 119125.30000
売上高 売上高(百万ドル) 32753.00000
企業価値(EV) 企業価値(EV)(百万ドル) 151374.30000
当期純利益 当期純利益(百万ドル) 5743.00000
決算概要 決算概要 BRIEF: For the fiscal year ended 31 December 2018 AbbVie Inc revenues increased 16% to $32.75B. Net income applicable to common stockholders excluding extraordinary items increased 1% to $5.74B. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income was partially offset by Research and development - Balanci increase from $4.82B to $10.16B (expense) Selling.

 ABBVのテクニカル分析


 ABBVのニュース

   AbbVie Files US, Europe Applications For Skyrizi In Psoriatic Arthritis  2021/04/07 14:42:08 Benzinga
AbbVie Inc (NYSE: ABBV ) has submitted marketing applications to the FDA and European Medicines Agency (EMA) seeking approval for Skyrizi (risankizumab-rzaa, 150 mg) … Full story available on Benzinga.com
   Top Analyst Upgrades and Downgrades: AbbVie, Alcoa, Applied Materials, Fox, Merck, Paychex, ViacomCBS and More – 24/7 Wall St.  2021/04/07 12:47:19 24/7 Wall street
Wednesday's top analyst upgrades and downgrades included AbbVie, Alcoa, Anheuser Busch, Applied Materials, CyberArk, Fox, Merck, Paychex, ViacomCBS and Waste Management.
   AbbVie's Upadacitinib US Application Review In Atopic Dermatitis Postponed  2021/04/05 11:25:55 Benzinga
The FDA has extended the review period for AbbVie Inc's (NYSE: ABBV ) supplemental marketing application seeking upadacitinib approval to treat adults and adolescents with moderate to severe atopic … Full story available on Benzinga.com
   Reproductive Hormone Market Next Big Thing | Major Giants AbbVie Inc., Allergan plc, Pfizer Inc., Novo Nordisk A/S, Endo Pharmaceuticals Inc  2021/03/23 10:25:38 OpenPR
CMI Published Latest Global Reproductive Hormone Market Study by in-depth analysis about current scenario, the Market size, demand, growth pattern, trends, and forecast. Revenue for Reproductive Hormone Market has grown substantially over the seven years to 2020 as a result
   'Halftime Report' Final Trades: Roku, AbbVie And More  2021/03/22 17:17:01 Benzinga
On CNBC's "Fast Money Halftime Report," the investment committee gave their final trades of the day. Odyssey Capital Advisors' Jason Snipe likes AbbVie Inc. (NYSE: ABBV ) and notes he likes the Allergan acquisition and the 5% yield. Requisite Capital Management Bryn Talkington likes Roku, Inc. (NASDAQ: Full story available on Benzinga.com
   AbbVie Seeks To Offload Allergan's Women's Health Unit: Reuters  2021/03/16 12:13:00 Benzinga
With blockbuster Humira’s U.S. patent coming closer to expiry, AbbVie Inc’s (NYSE: ABBV) is reportedly in talks to sell the …
   Global Leukemia Therapeutics Market by Manufacturers |Novartis AG, AbbVie, Bristol-Myers Squibb, F. Hoffmann-La Roche, Sanofi, Pfizer, Amgen, Gilead Sciences, Takeda, Celgene  2021/03/15 16:33:36 OpenPR
Leukemia Therapeutics Market research report delivers a comprehensive study on production capacity, consumption, import and export for all major regions across the world. Report provides is a professional inclusive study on the current state for the market. Analysis and discussion
   Barron's Latest Picks And Pans: Apple, Coupang, GameStop, Uber, Walker & Dunlop And More  2021/03/13 20:43:21 Benzinga
This weekend's Barron's cover story discusses how the U.S. economy could soar as the pandemic fades. Other featured articles discuss why big pharmaceutical stocks are cheap, the outlook for the aerospace industry and what comes next for three meme stocks. Also, the prospects for an apartment lender, a South Korean e-commerce giant, the iPhone maker and more. " It Has Been a Year Since Covid Gripped America. Why the Road Ahead Looks Bright " by Ben Levisohn discusses why, as the pandemic starts to wane, the U.S. economy could soar. See what that means for investors in the likes of Discover Financial Services (NYSE: DFS ), Mcdonald's Corp (NYSE: MCD ) and Zoom Video Communications Inc (NASDAQ: ZM ). Andrew Bary's " Big Pharma Battled the Pandemic. The Stocks Are Cheap " makes the case that drugmakers from AbbVie Inc (NYSE: ABBV ) to Amgen, Inc. (NASDAQ: AMGN ) and Bristol-Myers Squibb Co (NYSE: BMY ) have huge cash flows and strong pipelines. See which pharma stocks Barron's favors. In " Why This Apartment Lender Is a 'Money-Making Machine' ," Daren Fonda suggests that Maryland-based Walker & Dunlop, Inc. (NYSE: WD ) is growing strongly in the market for multifamily lending.
   Ireland’s best places to work in 2021 revealed  2021/03/11 15:50:13 SiliconRepublic
Cisco has nabbed first place in Great Place to Work’s large companies category, followed by Workhuman, Abbvie and Salesforce. The post Ireland’s best places to work in 2021 revealed appeared first on Silicon Republic .
   Pete Najarian Sees Unusual Option Activity In Unum And AbbVie  2021/03/05 17:52:13 Benzinga
On CNBC's "Fast Money Halftime Report," Pete Najarian gave some unusual option activity plays. Najarian sees unusual activity in: Unum … Full story available on Benzinga.com
   Examine Global Sterile Injectables Market is Anticipated to Reach $510 Billion by the End of 2025 | International Key Vendors - Pfizer, J&J, AbbVie, Sanofi, Eli Lilly, Merck, Roche  2021/03/04 16:38:29 OpenPR
All information provided in the report is derived from trusted industrial sources. Global Sterile Injectables Market research reports finds market figures between 2021 and 2025. The market will exhibit remarkable CAGRs in the aforementioned period. Global Sterile Injectables Market Overview: The Global
   A Jennifer Doudna-launched upstart nabs $115M for off-the-shelf CAR-Ts  2021/03/03 13:00:06 Endpoints News
There is no shortage of biotechs pursuing off-the-shelf CAR-Ts, a so-called Holy Grail in oncology R&D. Now, less than a month after teaming up with AbbVie, a California player launched by CRISPR pioneer Jennifer Doudna has returned to the venture well, scooping up a big crossover round to help it
   Blood Cancer Drugs Market With Key Players like Johnson & Johnson, Amgen, Bayer AG., Pfizer, AbbVie Inc., Roche Holding AG., Celgene Corporation, AstraZeneca, Novartis AG, GlaxoSmithKline PLC  2021/03/03 07:46:59 OpenPR
An off-the-shelf report on Blood Cancer Drugs Market which has been compiled after an in-depth analysis of the market trends prevailing across five geographies (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). Various segments of the market such
   Global Biologic API Contract Manufacturer 2020 Market - Featuring Abbvie, Boehringer Ingelheim and Catalent Among Others - ResearchAndMarkets.com  2021/03/02 17:19:00 Business Wire
DUBLIN--(BUSINESS WIRE)--The "Biologic API Contract Manufacturer Quality Benchmarking (6th Edition)" report has been added to ResearchAndMarkets.com's offering. This Biologic API Contract Manufacturing Quality Benchmarking (6th Edition) report brings with it a wealth of knowledge and information created with two goals in mind, help biopharmaceutical companies make more informed CMO decisions, and help CMOs optimize operational and marketing strategies. This report provides pharmaceutical compan
   AbbVie tees up a biotech buyout after sizing up their Parkinson's drug spun out of Kevan Shokat's lab  2021/03/02 14:20:06 Endpoints News
AbbVie has teed up a small but intriguing biotech buyout after looking over the preclinical work it’s been doing in Parkinson’s disease. The company is called Mitokinin, a Bay Area biotech spun out of the lab of UCSF’s Kevan Shokat, whose scientific explorations have formed the academic basis of a

 関連キーワード  (医薬品 米国株 ABBV アッヴィ ABBV )

 twitter  (公式ツイッターやCEOツイッターなど)